Xinyue Biotech and Lida Pioneer Announce Strategic Collaboration for Joint Development of Novel Immuno-Oncology Therapeutics

Shenzhen CityXinyue BioXinyue Biotech Co., Ltd. (hereinafter referred to as “Xinyue Biotech”) and NingboLida PioneerBiotechnology Co., Ltd. (hereinafter referred to as "Lida XianDao") recently announced that the two parties have signed a new drug development cooperation agreement,Developing Cancer Immunotherapy Drugs Targeting Novel Targets。

This collaboration will bring Xinyue BiotechDNA-Encoded Library (DEL) and its proprietary live-cell screening technologies, alongside Lida Lead’s automation-driven chemoproteomics technologies and PROTAC target degradation analysis technologiesBy integrating these platforms, a DEL3.0+ProTAC/chemical proteomics R&D system with complementary advantages has been established. This system not only significantly shortens the optimization time for hit/lead compounds targeting novel targets, but also enables the identification of potential off-targets at the earliest stages of drug design, thereby avoiding toxic side effects or expanding into additional potential indications. The conclusion of this new drug co-development agreement represents another significant step by Xinyue Biopharma in integrating industry resources with complementary strengths.

He Xun, Chairman of New Yue Biotechstated: “We are delighted to enter into a new drug development collaboration agreement with Lida Pioneer. This partnership aims to develop immunotherapeutic agents targeting novel targets, thereby exploring the significant value of DEL3.0 and PROTAC/chemical proteomics technologies in the field of new drug discovery. Xinyue Bio will continue to integrate industry resources, leveraging the inherent advantages of DEL3.0 in achieving 0-to-1 breakthroughs for new targets and novel scaffolds, to rapidly design and optimize preclinical candidate compounds (PCCs) through resource integration. This collaboration marks another milestone in the steady advancement of Xinyue Bio’s joint new drug development business model, following the previous success with DEL3.0 combined with stable membrane protein expression technology.”

Dr. Ni Feng, CEO of Lida XianDaostated: “The collaboration between Lida XianDao and XinYue Biologics in new drug development fully integrates both parties’ R&D characteristics, strengths, and accumulated technologies and data in novel drug discovery, to jointly develop innovative PROTAC drugs targeting novel mechanisms. Meanwhile, the two parties have established a win-win strategic partnership based on shared development goals, which will evolve into a more competitive model for innovative collaboration in new drug development.”

Shenzhen Xinyue Biotechnology Co., Ltd. was established in April 2021 as the first biopharmaceutical company incubated by the Guangdong Provincial Small Molecule New Drug Innovation Center. Leveraging its independently developed DEL3.0 library construction platform and proprietary live-cell screening technology, Xinyue Biotechnology has established a comprehensive lifecycle system for innovative drug design, R&D, and commercialization, focusing on first-in-class (FIC) therapies to address unmet clinical needs. The company is committed to becoming an internationally leading and distinctly characterized biopharmaceutical enterprise dedicated to novel drug discovery and development.

Lida Pioneer was established in Los Angeles, USA, and Ningbo, China, in 2017. It is the first biotechnology company in China and among the earliest globally to leverage chemical proteomics technologies for the discovery of novel protein targets and the development of new drugs. By integrating cutting-edge biochemical and automation technologies, Lida Pioneer is committed to building a world-leading automated and intelligent drug discovery platform. Utilizing its proprietary “target-fishing probe” technology for proteomics, the company enables rapid screening of new drug candidates at the level of the human live-cell proteome. Building on its self-developed library of active molecular probes and expertise in elucidating drug mechanisms, Lida Pioneer has advanced its pipeline development through collaborations with more than ten pharmaceutical companies, research institutions, and AI-driven drug discovery firms across China, the United States, and South Korea.